EBMT NEWSLETTER | September 2015 | Volume 48 - Issue 3

EBMT
Important dates
Outcome and risk factor analysis of molecular subgroups in cytogenetically normal AML treated by allogeneic transplantation.
Schmid C, Labopin M, Socié G, Daguindau E, Volin L, Huynh A, Bourhis JH, Milpied N, Cornelissen J, Chevallier P, Maertens J, Jindra P, Blaise D, Lenhoff S, Ifrah N, Baron F, Ciceri F, Gorin C, Savani B, Giebel S, Polge E, Esteve J, Nagler A, Mohty M.
Blood. 2015 Sep 8. pii: blood-2015-06-651562. [Epub ahead of print]. PMID: 26351297 
 
Patients with cytogenetically normal acute myeloid leukemia (CN-AML) can be subdivided by molecular mutations. However, data on the influence of combinations of different aberrations on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) is limited. This retrospective analysis of the Acute Leukemia Working Party of the EBMT on 702 adult patients with CN-AML undergoing HSCT in first complete remission (CR) gives a reliable prognostic estimate of the outcome in different, well defined molecular subgroups of patients with CN-AML after alloHSCT in CR1, with a remarkable impact of age and FLT3-ITD. Although the study was not designed to answer the question of whether or not patients with certain molecular subgroups should or should not undergo alloHSCT in CR1, it might provide a basis for the decision between transplant and non-transplant consolidation strategies by giving a clear idea of the outcome to be expected after alloHSCT in a certain patient.


Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an ebmt/eln international working group.
Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G.
Leukemia. 2015 Aug 21. doi: 10.1038/leu.2015.233. [Epub ahead of print] Review. PMID: 26293647
 
Although allogeneic hematopoietic stem cell transplantation (allo-SCT) is a well-established treatment modality for primary myelofibrosis (PMF) and the only potentially curative treatment although there are no prospective clinical trials that compare the clinical benefit of allo-SCT in front of other non-transplant strategies. The aim of this consensus document was to produce recommendations regarding the use of allo-SCT in this disease. A panel of 23 experts appointed by the European LeukemiaNet (ELN) and European Blood and Marrow Transplantation Group (EBMT) performed a comprehensive systematic review of articles released from Jan 1999 to Jan 2015 and recommendations were produced using a Delphi process. Candidates for allo-SCT were those with intermediate-2- or high-risk disease and age less than 70 years and those with intermediate-1-risk disease and age less than 65 years if they present with either refractory, transfusion-dependent anemia, or a percentage of circulating blasts greater than 2%, or adverse cytogenetics.  The need of pre-transplant splenectomy, the use of alternative donors, stem cell source, dose intensity of the conditioning régimen as well as follow up after the allogeneic procedure were also discussed. This manuscript highlights the clinical relevance of consensus documents in the abscence of stronger evidence in the field base don prospective clinical trials.
 
Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT.
Dufour C, Veys P, Carraro E, Bhatnagar N, Pillon M, Wynn R, Gibson B, Vora AJ, Steward CG, Ewins AM, Hough RE, de la Fuente J, Velangi M, Amrolia PJ, Skinner R, Bacigalupo A, Risitano AM, Socie G, Peffault de Latour R, Passweg J, Rovo A, Tichelli A, Schrezenmeier H, Hochsmann B, Bader P, van Biezen A, Aljurf MD, Kulesekararaj A, Marsh JC, Samarasinghe S.
Br J Haematol. 2015 Jul 28. doi: 10.1111/bjh.13614. [Epub ahead of print]. PMID: 26223288

Unrelated donor hematopoietic stem cell transplantation (HSCT) is currently reserved for children with idiopathic severe aplastic anemia (SAA) who fail immunosuppressive therapy (IST). However, over the last two decades there has been a considerable improvement in outcomes following matched unrelated donor (MUD) and mismatched unrelated donor (MMUD) HSCT for pediatric idiopathic SAA. Long term outcome of a UK cohort of 29 consecutive children with idiopathic SAA who received a MUD-HSCT as ?rst-line therapy was compared with the outcome of historical matched controls that had been reported to the EBMT Database Registry who had received either front-line matched sibling donor (MSD) HSCT (n = 87), front-line IST with horse anti-thymocyte globulin and ciclosporin A (n = 58) or MUD HSCT post-IST failure as second-line therapy (n = 24). 2-year overall survival (OS) was not significantly different between children being treated with a MSD HSCT and those receiving cells from a MUD; OS was significantly worse when MUD HSCT was considered as a second treatment option, after IST failure. No differences were seen between both types of HSCT in 2-year event free survival (EFS) either. 2-year EFS was significantly worse for those children being treated with IST and with a MUD HSCT because of IST failure. The results of this retrospective analysis suggest that upfront MUD HSCT could be considered a first-line treatment options in selected pediatric patients with idiopathic SAA who lack a matched sibling donor thus increasing the potential group of patients candidates for a HSCT as first treatment option.

EBMT PubMed Publications

From July 15th, 2015 to September 15th, 2015

Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.
Ravelli A, et al.
Tumour Biol. 2015 Aug 26. [Epub ahead of print] PMID: 26307395
 
Outcome and risk factor analysis of molecular subgroups in cytogenetically normal AML treated by allogeneic transplantation.
Schmid C, et al.
Blood. 2015 Sep 8. pii: blood-2015-06-651562. [Epub ahead of print] PMID: 26351297 
 
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an ebmt/eln international working group.
Kröger NM, et al.
Leukemia. 2015 Aug 21. doi: 10.1038/leu.2015.233. [Epub ahead of print] Review.
PMID: 26293647
 
Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors than with HLA-identical siblings?
Ringdén O, et al.
Leukemia. 2015 Aug 21. doi: 10.1038/leu.2015.232. [Epub ahead of print] PMID: 26293645 
 
Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects.
Gorin NC, et al.
Bone Marrow Transplant. 2015 Aug 17. doi: 10.1038/bmt.2015.179. [Epub ahead of print] Review. PMID: 26281031
 
Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases.
Slatter MA, et al.
Bone Marrow Transplant. 2015 Aug 10. doi: 10.1038/bmt.2015.171. [Epub ahead of print] PMID: 26259076 
 
Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT.
Dufour C, et al.
Br J Haematol. 2015 Jul 28. doi: 10.1111/bjh.13614. [Epub ahead of print]
PMID: 26223288 
 
Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.
Auner HW, et al.
Br J Haematol. 2015 Jul 27. doi: 10.1111/bjh.13608. [Epub ahead of print]
PMID: 26213240
 
Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.
Sengsayadeth S, et al.
Haematologica. 2015 Jul;100(7):859-69. doi: 10.3324/haematol.2015.123331. Review.
PMID: 26130513  
 
Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.
Passweg JR, et al.
Bone Marrow Transplant. 2015 Aug;50(8):1063-8. doi: 10.1038/bmt.2015.121. Epub 2015 Jun 1. PMID: 26030052 
 
Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).
Poiré X, et al.
Am J Hematol. 2015 Aug;90(8):719-24. doi: 10.1002/ajh.24069. PMID: 26010466 
 
Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Kharfan-Dabaja MA, et al.
Leuk Res. 2015 Sep;39(9):933-7. doi: 10.1016/j.leukres.2015.04.009. Epub 2015 Apr 24. PMID: 26003666 
 
Current practices used for the prevention of central venous catheter-associated infection in hematopoietic stem cell transplantation recipients: a survey from the Infectious Diseases Working Party and Nurses' Group of EBMT.
Snarski E, et al.
Transpl Infect Dis. 2015 Aug;17(4):558-65. doi: 10.1111/tid.12399. Epub 2015 Jun 18. PMID: 25953418 
 
Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial.
Cordonnier C, et al.
Bone Marrow Transplant. 2015 Jul;50(7):978-83. doi: 10.1038/bmt.2015.42. Epub 2015 Apr 13. PMID: 25867652

Click on the link below to view all the EBMT publications:
http://www.ebmt.org/Contents/Research/Publications/Pages/PublicationsSelector.aspx
Bookmark and Share